美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

OncoMed Pharmaceuticals, Inc.

0.8900

0.0000

成交量：- -

成交額：- -

市值：3,443.42萬

市盈率：-4.22

高：0.8900

開：0.8900

低：0.8900

收：0.8900

52周最高：3.35

52周最低：0.5467

股本：3,869.01萬

流通股本：2,608.64萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.2107

每股收益(LYR):-0.2107

淨資產收益率：--

總資產收益率：--

市淨率：0.71

市盈率(LYR):-4.22

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

OncoMed Pharmaceuticals, Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.oncomed.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Oncomed Pharmaceuticals, Inc.作為一家臨床階段的生物技術公司於2004年7月在特拉華州成立。公司致力於發現和開發對抗腫瘤干細胞的類單克隆抗體藥物。公司的業務和工作地點位於加利福尼亞州紅木城。其候選產品的目標是干細胞自我更新和通過阻斷腫瘤干細胞和大部分腫瘤細胞，以驅動細胞向非致瘤性狀態分化。公司認為，其候選產品不同於目前的化療，有顯著影響癌症治療與臨床結果的可能。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/OMED/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OMED\",,,,,undefined,":{"symbol":"OMED","market":"US","secType":"STK","nameCN":"OncoMed Pharmaceuticals, Inc.","latestPrice":0.89,"timestamp":1557432000000,"preClose":0.89,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":26086382,"shares":38690089,"eps":-0.210727,"marketStatus":"停牌","change":0,"latestTime":"03-24 09:46:22 EDT","open":0.89,"high":0.89,"low":0.89,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.210727,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774382400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1374120000000,"exchange":"NASDAQ","adjPreClose":0.89,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OMED\",,,,,undefined,":{"symbol":"OMED","floatShares":26086382,"roa":"--","roe":"--","lyrEps":-0.210727,"shares":38690089,"dividePrice":0,"high":0.89,"amplitude":0,"preClose":0.89,"low":0.89,"week52Low":0.5467,"pbRate":"0.71","week52High":3.35,"institutionHeld":0,"latestPrice":0.89,"eps":-0.210727,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.210727,"open":0.89,"prevYearClose":0.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OMED\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-03-07","symbol":"OMED","fiscalQuarterEnding":"2018/12","expectedEps":-0.22,"name":null,"time":"","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"","actualEps":-0.07},{"market":"US","date":"2018-11-01","symbol":"OMED","fiscalQuarterEnding":"2018/09","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1541044800000,"reportTimeType":"","actualEps":0.16},{"market":"US","date":"2018-08-02","symbol":"OMED","fiscalQuarterEnding":"2018/06","expectedEps":-0.23,"name":null,"time":"","type":"earning","dateTimestamp":1533182400000,"reportTimeType":"","actualEps":-0.1},{"market":"US","date":"2018-05-08","symbol":"OMED","fiscalQuarterEnding":"2018/03","expectedEps":-0.25,"name":null,"time":"盤後","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2018-03-08","symbol":"OMED","fiscalQuarterEnding":"2017/12","expectedEps":-0.31,"name":null,"time":"盤後","type":"earning","dateTimestamp":1520485200000,"reportTimeType":"post","actualEps":0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OMED\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OMED\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.oncomed.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Oncomed Pharmaceuticals, Inc.作為一家臨床階段的生物技術公司於2004年7月在特拉華州成立。公司致力於發現和開發對抗腫瘤干細胞的類單克隆抗體藥物。公司的業務和工作地點位於加利福尼亞州紅木城。其候選產品的目標是干細胞自我更新和通過阻斷腫瘤干細胞和大部分腫瘤細胞，以驅動細胞向非致瘤性狀態分化。公司認為，其候選產品不同於目前的化療，有顯著影響癌症治療與臨床結果的可能。","exchange":"NASDAQ","name":"OncoMed Pharmaceuticals, Inc.","nameEN":"OncoMed Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OMED\",market:\"US\",,,undefined,":null}}